We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Injectable Drug Delivery Market Set for Healthy Growth

By Biotechdaily staff writers
Posted on 20 Mar 2007
Led by the strong growth of biotechnology drugs requiring novel delivery technologies, the injectable/implantable drug delivery market is steadily growing, says a new market research study by Kalorama Information (New York, NY, USA), an independent market research company on medical markets.

The market is dominated by implantable, sustained-release, and targeted-injection drug delivery systems with manufacturer revenues of approximately US$7.3 billion in 2006, an increase of 6.3% over 2002 sales. More...
Growth continues to be fueled by the introduction of biologic therapies, including blood modifiers and insulin products, with the sector projected to reach $9 billion by 2010. An expanding drug delivery marketplace, increasing consumer awareness, and growing focus on healthcare worker safety could help drive additional demand for needle-free systems, with revenues expected to reach $3 billion by 2010.

"The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to significant improvements in drug delivery,” said report author Mary Anne Crandall. "This is a dynamic market expected to increase at break-neck speed during the forecast period. Significant revenue increases are anticipated particularly in the needle-free delivery of injectable medications, especially in the vaccine arena.”

Implantable technologies have been successfully utilized in administering anti-cancer therapeutics as well as the administration of high drug doses in traditionally inaccessible areas, such as the central nervous system, bone tissue, and beyond the blood–retinal barrier.


Related Links:
Kalorama Information

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.